Company intelligence / Profile preview

Navitas Capital

Princeton, New Jersey, United States

Ownership: Private
Employees: ~1000
Development stage: Other

Overview

Navitas Life Sciences is a global technology-led clinical research organization (CRO) that provides comprehensive services to the pharmaceutical, biotechnology, and medical device industries. The company specializes in clinical trial management, regulatory affairs, and pharmacovigilance, utilizing its proprietary technology platforms like OneClinical and PharmaReady to streamline drug development processes. Navitas is also recognized for its industry-leading benchmarking networks, known as 'nets,' which offer valuable insights and best practices to life sciences executives. Following its acquisition by H.I.G. Capital in 2021, the company has continued to expand its digital capabilities and global footprint to support the evolving needs of the healthcare sector.

Industry: Contract Research Organization

Beyond the preview

Go deeper on Navitas Capital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Navitas Capital.

Explore the full profile